Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology.
Pasqualetti F, Pace A, Gonnelli A, Villani V, Cantarella M, Delishaj D, Vivaldi C, Molinari A, Montrone S, Pellerino A, Franchino F, Baldaccini D, Lombardi G, Lolli I, Catania F, Bazzoli E, Morganti R, Fabi A, Zagonel V, Bocci G, Fabrini MG, Rudà R, Soffietti R, Paiar F. Pasqualetti F, et al. Among authors: lolli i. Am J Clin Oncol. 2018 Dec;41(12):1272-1275. doi: 10.1097/COC.0000000000000464. Am J Clin Oncol. 2018. PMID: 29782366
A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib.
Santangelo A, Rossato M, Lombardi G, Benfatto S, Lavezzari D, De Salvo GL, Indraccolo S, Dechecchi MC, Prandini P, Gambari R, Scapoli C, Di Gennaro G, Caccese M, Eoli M, Rudà R, Brandes AA, Ibrahim T, Rizzato S, Lolli I, Lippi G, Delledonne M, Zagonel V, Cabrini G. Santangelo A, et al. Among authors: lolli i. Neuro Oncol. 2021 Feb 25;23(2):264-276. doi: 10.1093/neuonc/noaa156. Neuro Oncol. 2021. PMID: 32661549 Free PMC article.
Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol.
Bongiovanni A, Liverani C, Pusceddu S, Leo S, Di Meglio G, Tamberi S, Santini D, Gelsomino F, Pucci F, Berardi R, Lolli I, Bergamo F, Ricci S, Foca F, Severi S, Ibrahim T; SENECA Study Team Investigators. Bongiovanni A, et al. Among authors: lolli i. BMJ Open. 2020 Jul 19;10(7):e034393. doi: 10.1136/bmjopen-2019-034393. BMJ Open. 2020. PMID: 32690499 Free PMC article.
REGOMA-OSS: a large, Italian, multicenter, prospective, observational study evaluating the efficacy and safety of regorafenib in patients with recurrent glioblastoma.
Caccese M, Desideri I, Villani V, Simonelli M, Buglione M, Chiesa S, Franceschi E, Gaviani P, Stasi I, Caserta C, Brugnara S, Lolli I, Bennicelli E, Bini P, Cuccu AS, Scoccianti S, Padovan M, Gori S, Bonetti A, Giordano P, Pellerino A, Gregucci F, Riva N, Cinieri S, Internò V, Santoni M, Pernice G, Dealis C, Stievano L, Paiar F, Magni G, De Salvo GL, Zagonel V, Lombardi G. Caccese M, et al. Among authors: lolli i. ESMO Open. 2024 Apr;9(4):102943. doi: 10.1016/j.esmoop.2024.102943. Epub 2024 Mar 15. ESMO Open. 2024. PMID: 38492275 Free PMC article.
Quality of life, compliance, safety and effectiveness in fit older metastatic colorectal patients with cancer treated in first-line with chemotherapy plus cetuximab: A restrospective analysis from the ObservEr study.
Rosati G, Pinto C, Di Fabio F, Chiara S, Lolli IR, Ruggeri EM, Ciuffreda L, Ferrara R, Antonuzzo L, Adua D, Racca P, Bilancia D, Benincasa E, Stroppolo ME, Di Costanzo F. Rosati G, et al. J Geriatr Oncol. 2018 May;9(3):243-248. doi: 10.1016/j.jgo.2018.01.009. Epub 2018 Feb 9. J Geriatr Oncol. 2018. PMID: 29433905 Free article.
31 results